High-intensity functional interval training in heart failure

High-intensity functional interval training in heart failure with reduced ejection fraction of less than 40%

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN39426207

Enrollment

Registered

2021-03-04

Start date

2018-06-01

Completion date

Unknown

Last updated

2024-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Secondary prevention of heart failure with a reduced ejection fraction Circulatory System Left ventricular failure

Interventions

Participants were recruited to the pilot study for HF-HIFIT from June 2018. This preliminary data was analysed and will be included in the results of the main trial. Recruitment to the main trial was

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged between 18 and 75 years 2. Stable heart failure with an ejection fraction between 20% and 40% 3. New York Heart Association (NYHA) functional class of heart failure between I and III, with optimal treatment at the maximum tolerated dose (including defibrillator or resynchronization therapy) 4. No major cardiovascular event, hospitalization, or cardiovascular intervention in the last 3 months prior to randomization without additional need for short-term (6 months) revascularization

Exclusion criteria

Exclusion criteria: 1. Inability to exercise 2. Atrial fibrillation with a ventricular response at rest >110 beats per min at rest 3. Appropriate shock of the defibrillator in the past 3 months 4. Patient dependent on the pacemaker 5. Uncontrolled diabetes 6. Insulin pump 7. Uncontrolled arterial hypertension, systolic blood pressure >160 mmHg 8. On hemodialysis 9. Left ventricular enlargement or septal enlargement (>18 mm) or any obstruction of the left ventricle 10. Right ventricular pressure >60 mmHg 11. Severe valve disease based on ultrasound diagnosis 12. Addiction to an illegal drug 13. Inability to read and understand the consent form 14. Any situation where the principal investigator perceives that the patient will not adhere to the protocol

Design outcomes

Primary

Measure	Time frame
1. Effectiveness is measured with cardiovascular tests including echography and cardiopulmonary tests such as maximal oxygen uptake (VO2max) at baseline and 3 months	—

Secondary

Measure	Time frame
1. Quality of life measured using the World Health Organization Quality of Life (WHOQOL) questionnaire at baseline and 3 months 2. Functional capacity measured using the 6-min walk test and the Timed Up and Go test at baseline and 3 months	—

Countries

Canada

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026